As of November 6, 2026, NeuroPace Inc is a publicly traded company (Nasdaq: NPCE); its largest reported holder is Mathew P. Arens, with 12.25% on Schedule 13G/A of September 4, 2026, then Soleus Capital Management, L.P. (8.9%). The largest insider holding is Uri Geiger, a director, with 4,451,485 shares (13.0% of shares outstanding), per Form 4 of June 22, 2026 (Schedule 13G/A, September 4, 2026).
Is this your company?
About to sign with, pay or invest in NeuroPace Inc? See the free Snapshot first.
Free to see. No signup.
Is NeuroPace Inc a real, registered company?
- NeuroPace Inc files with the SEC under CIK 1528287 (its SEC filings).
- Its shares are listed under the ticker NPCE on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Mountain View, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under NeuroPace Inc in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Mathew P. Arens (filed 2026-09-04).
Who are NeuroPace Inc's owners and officers?
NeuroPace Inc: incorporated in Delaware; business address in Mountain View, California; industry Surgical & Medical Instruments & Apparatus (Schedule 13G/A, 2026-09-04).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-09-04 | Mathew P. Arens | 12.25% |
| Schedule 13G/A, 2026-08-14 | Orbimed Advisors LLC | 4.4% |
| Schedule 13G, 2026-05-15 | Mathew P. Arens | 8.67% |
| Schedule 13G/A, 2026-05-15 | Orbimed Advisors LLC | 6.2% |
| Schedule 13G/A, 2025-11-07 | Soleus Capital Management, L.P. | 8.9% |
| Schedule 13G/A, 2025-09-03 | Kck LTD. | 0% |
| Schedule 13G/A, 2025-08-14 | Orbimed Advisors LLC | 8% |
| Schedule 13G/A, 2025-08-05 | Soleus Capital Management, L.P. | 7% |
Questions about who owns NeuroPace Inc
Who owns NeuroPace Inc?
On this page, 2 holders' latest ownership filings report 5% or more of NeuroPace Inc: Mathew P. Arens (12.25%, Schedule 13G/A, filed 2026-09-04) and Soleus Capital Management, L.P. (8.9%, Schedule 13G/A, filed 2025-11-07).
Who are the largest shareholders of NeuroPace Inc?
By the share each holder's latest filing reports, the largest holders of NeuroPace Inc on this page are Mathew P. Arens (12.25%) and Soleus Capital Management, L.P. (8.9%).
When did Mathew P. Arens buy into NeuroPace Inc?
The filings give report dates, not purchase dates. The earliest filing from Mathew P. Arens on this page is the Schedule 13G, filed 2026-05-15, reporting 8.67%; its latest, Schedule 13G/A filed 2026-09-04, reports 12.25%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on NeuroPace Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on NeuroPace Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NeuroPace Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own NeuroPace Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 4,451,485 shares (13.0% of shares outstanding), 18,537 held directly and 4,432,948 indirectly (Form 4, 2026-06-22).
- OrbiMed, a 10% owner: 3,238,199 shares (9.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-05-16).
- OrbiMed Capital GP VI LLC, a 10% owner: 3,238,199 shares (9.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-05-16).
- , a director: 599,534 shares (1.7% of shares outstanding) (Form 4, 2026-06-22).
- , a director: 238,308 shares (0.69% of shares outstanding), 14,754 held directly and 223,554 indirectly (Form 4, 2026-03-24).
Shares outstanding: 34,324,274 as of 2026-08-07, from the company's latest SEC cover page.
How much has NeuroPace Inc raised?
No fundraising or offering filing from NeuroPace Inc is on file with us.
Keep reading
More on NeuroPace Inc and the records around it.
NeuroPace Inc elsewhere on the record
- 5%+ stake filings Sep 2026
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: Neogenomics, Inc. (Aug 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026), TriSalus Life Sciences, Inc. (Jul 2026)
- Soleus Private Equity Fund I, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- OrbiMed Advisors LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/neuropace